Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized study comparing oral valganciclovir versus intravenous ganciclovir after allogeneic stem cell transplantation
2009-015965-29Phase 3Terminated
- Sponsor
- Pierrel
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of valganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Pierrel. Primary endpoint: Primary combined efficacy and safety endpoint. Started Feb 2010; status: terminated.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2009-015965-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015965-29.